Showing results (11-20 of 201) with videos related to

Sort By:
Pageof 21
Current Hematologic Malignancy Reports|May 16, 2023
A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid Leukemia TreatmentJosephine Anne Lucero, Jeffrey H Lipton
Targeted Oncology|January 17, 2025
Bosutinib for the Treatment of CML-Using it Safely: a PodcastJeffrey H Lipton, Jorge E Cortes
Journal of the National Comprehensive Cancer Network : JNCCN|October 6, 2020
Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All?Alejandro Garcia-Horton, Jeffrey H Lipton
American Journal of Hematology|November 6, 2018
Treatment-free remission with first- and second-generation tyrosine kinase inhibitorsJorge Cortes, Delphine Rea, Jeffrey H Lipton
Expert Opinion on Emerging Drugs|February 27, 2018
Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemiaSimon Kavanagh, Aisling Nee, Jeffrey H Lipton
Journal of Medical Case Reports|September 18, 2015
Inclusion body myositis in a patient with chronic myeloid leukemia treated with dasatinib: a case reportNaif I AlJohani, Simon Carette, Jeffrey H Lipton
Clinical Case Reports|October 31, 2014
Imatinib-induced gastric antral vascular ectasia in a patient with chronic myeloid leukemiaNawal F Alshehry, Paul Kortan, Jeffrey H Lipton
International Journal of Hematology|March 4, 2015
A case report and literature review of chronic graft-versus-host disease manifesting as polymyositisFotios V Michelis, Vera Bril, Jeffrey H Lipton
Expert Opinion on Drug Safety|July 2, 2016
A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemiaMoussab Damlaj, Jeffrey H Lipton, Sarit E Assouline
Pageof 21